Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

236
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
236
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

158
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
158
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

280
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
280
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

129
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
129
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.4K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes.

Arthritis research & therapy·2024
Same author

The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study.

BMC cancer·2024
Same author

DNA methylation is associated with codon degeneracy in a species of bumblebee.

Heredity·2023
Same author

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity.

Seminars in arthritis and rheumatism·2021
Same author

Effect of clinical signs, endocrinopathies, timing of surgery, hyperlipidemia, and hyperbilirubinemia on outcome in dogs with gallbladder mucocele.

Veterinary journal (London, England : 1997)·2019

Related Experiment Video

Updated: Dec 30, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K

Systemic sclerosis: Advances towards stratified medicine.

A Quinlivan1, L Ross2, S Proudman3

  • 1Rheumatology Unit, Royal Adelaide Hospital, Port Road, SA 5000, Australia.

Best Practice & Research. Clinical Rheumatology
|January 25, 2020
PubMed
Summary

Predicting systemic sclerosis (SSc) progression is challenging. New subgroupings using high-dimensional data and biomarkers may enable personalized treatment strategies and improve clinical trials for SSc patients.

Keywords:
Disease progressionOutcome measuresPhenotypingSystemic sclerosis

More Related Videos

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.5K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

688

Related Experiment Videos

Last Updated: Dec 30, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.5K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

688

Area of Science:

  • Rheumatology and Immunology
  • Translational Medicine
  • Biomarker Discovery

Background:

  • Systemic sclerosis (SSc) patient outcomes, including mortality and disease progression, are influenced by demographic, clinical, and serological factors.
  • Predicting individual SSc disease trajectory is crucial for stratified management but remains a significant challenge.

Purpose of the Study:

  • To explore the potential of recent technological advancements in subgrouping SSc patients for risk stratification.
  • To identify non-invasive biomarkers for predicting organ involvement, disease activity, and treatment response in SSc.
  • To enhance clinical trial design and facilitate the identification of targeted therapies for SSc.

Main Methods:

  • Systematic analysis of high-dimensional clinical data integrated with genetic, transcriptomic, and proteomic information.
  • Exploration of novel non-invasive biomarkers for disease assessment.
  • Standardization of outcome measures in patient selection for clinical trials.

Main Results:

  • Technological advances offer new possibilities for SSc patient subgrouping based on risk stratification.
  • High-dimensional data analysis combined with molecular information can identify predictive factors for SSc outcomes.
  • Identification of non-invasive biomarkers holds promise for monitoring disease activity and therapeutic response.

Conclusions:

  • Advanced data analysis and biomarker research can lead to a more personalized approach to SSc management.
  • Improved patient stratification and outcome standardization are key to advancing SSc clinical trial design.
  • Targeted therapies informed by molecular signatures and clinical phenotypes are expected to improve SSc treatment efficacy.